Palatin Technologies (PTN) Total Current Liabilities (2011 - 2026)
Palatin Technologies' (PTN) quarterly Total Current Liabilities came in at $2.5 million in Q1 2026, down 74.76% on a YoY basis from $10.0 million in Q1 2025, and down 59.95% quarter-over-quarter from $6.3 million in Q4 2025.
Analysis
Palatin Technologies (PTN) Total Current Liabilities (2011 - 2026) Analysis & Trends
Palatin Technologies (PTN) has reported Total Current Liabilities for 15 consecutive years, with $2.5 million the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, Total Current Liabilities fell 74.76% year-over-year to $2.5 million; the trailing twelve-month figure through Mar 2026 stood at $2.5 million (down 74.76% YoY), and the FY2025 full-year result was $8.0 million, down 17.06% from the prior year.
- Total Current Liabilities eased to $2.5 million in Q1 2026 per PTN's latest filing, from $6.3 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $16.3 million in Q2 2022 and bottomed at $2.5 million in Q1 2026.
- Historically, Total Current Liabilities has averaged $10.6 million across 5 years, with a median of $10.0 million in 2025.
- The sharpest annual moves came in 2022 and 2026: Total Current Liabilities soared 62.05% in 2022, then tumbled 74.76% in 2026.
- Over 5 years, Total Current Liabilities stood at $11.4 million in 2022, then fell by 1.93% to $11.2 million in 2023, then retreated by 14.65% to $9.6 million in 2024, then sank by 33.75% to $6.3 million in 2025, then slumped by 59.95% to $2.5 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $2.5 million, $6.3 million, and $8.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 25.50 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 11.02 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 3.94 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 5.53 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 1.58 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 2.53 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 1.51 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 3.92 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 283.60 Mn |
| 10 | Palatin Technologies | 46.98 Mn | 46.98 Mn | - | 2.54 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 2.54 Mn |
| Dec 31, 2025 | 6.33 Mn |
| Sep 30, 2025 | 8.22 Mn |
| Jun 30, 2025 | 8.01 Mn |
| Mar 31, 2025 | 10.05 Mn |
| Dec 31, 2024 | 9.56 Mn |
| Sep 30, 2024 | 9.86 Mn |
| Jun 30, 2024 | 9.66 Mn |
| Mar 31, 2024 | 8.53 Mn |
| Dec 31, 2023 | 11.20 Mn |
| Sep 30, 2023 | 13.61 Mn |
| Jun 30, 2023 | 15.13 Mn |
| Mar 31, 2023 | 11.85 Mn |
| Dec 31, 2022 | 11.42 Mn |
| Sep 30, 2022 | 15.86 Mn |
| Jun 30, 2022 | 16.26 Mn |
| Mar 31, 2022 | 11.98 Mn |
| Dec 31, 2021 | 13.86 Mn |
| Sep 30, 2021 | 9.79 Mn |
| Jun 30, 2021 | 10.51 Mn |